Dr. Al-Fayoumi has over 23 years of regulatory and industry experience including clinical pharmacology, biopharmaceutics, pharmacology, toxicology, and translational sciences. Dr. Al-Fayoumi spent 8 years as a Senior Clinical Pharmacology and Biopharmaceutics Reviewer at FDA, 4.5 years at Novartis Pharma, and 8 years at two small biotech companies, where he led the development of the JAK2/ FLT3 inhibitor pacritinib. He has extensive experience in designing, executing, and overseeing ADME/DMPK, nonclinical pharmacology and toxicology and clinical pharmacology PKPD study protocols, reports, programs and has received several awards recognizing his leadership abilities and outstanding work in regulatory science and contributions to drug development programs. Dr. Al-Fayoumi supported several regulatory submissions in his capacity as Clinical Pharmacologist and has extensive experience interacting with key regulatory health authorities including US FDA, EMA & PMDA. His therapeutic area expertise includes hematology, oncology, anesthetics, pain, cardiovascular, GI, CNS, ophthalmology, and metabolic disorders. Dr. Al-Fayoumi is a pharmacist in education and he received his Ph.D. in Pharmacokinetics from the University of Florida.